Tenax Therapeutics is trading 9.87% down at $1.92 after Guggenheim downgraded its rating from Buy to Neutral on August 31, 2026, citing uncertainty around LEVEL trial efficacy and regulatory approval.
- The downgrade followed additional subgroup data presented at the European Society of Cardiology Congress.
- Lower-baseline-walking patients showed improved exercise capacity, while the overall trial missed its primary endpoint.
- Trading is volatile during the August 31 session; broader markets are modestly lower, but company-specific analyst action and mixed clinical interpretation appear more relevant.